Neuroblastoma is an enigmatic disease entity; some tumors disappear spontaneously without any therapy, while others progress with a fatal outcome despite the implementation of maximal modern therapy. However, strong prognostic factors can accurately predict whether children have "good" or "bad" disease at diagnosis, and the clinical stage is currently the most signifi cant and clinically relevant prognostic factor. Therefore, for an individual patient, proper staging is of paramount importance for risk assessment and selection of optimal treatment. In 2009, the International Neuroblastoma Risk Group (INRG) Project proposed a new staging system designed for tumor staging before any treatment, including surgery. Compared with the focus of the International Neuroblastoma Staging System, which is currently the most used, the focus has now shifted from surgicopathologic fi ndings to imaging fi ndings. The new INRG Staging System includes two stages of localized disease, which are dependent on whether image-defi ned risk factors (IDRFs) are or are not present. IDRFs are features detected with imaging at the time of diagnosis. The present consensus report was written by the INRG Imaging Committee to optimize imaging and staging and reduce interobserver variability. The rationales for using imaging methods (ultrasonography, magnetic resonance imaging, computed tomography, and scintigraphy), as well as technical guidelines, are described. Defi nitions of the terms recommended for assessing IDRFs are provided with examples. It is anticipated that the use of standardized nomenclature will contribute substantially to more uniform staging and thereby facilitate comparisons of clinical trials conducted in different parts of the world. 
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Brisse et al diagnosis ( 9, 10 ) . Stage M indicates disseminated disease (comparable to the INSS stage 4), and stage MS indicates metastatic disease similar to INSS stage 4S disease (with exception of primary tumor size and patient age range). Compared with the focus on surgicopathologic fi ndings in the INSS, the focus has now shifted to imaging. Since imaging data can be retrospectively reviewed, a system based on preoperative diagnostic image fi ndings will be more robust and reproducible than one based on surgical fi ndings. In addition, because the digital imaging data can be reviewed centrally by expert radiologists, the likelihood of uniform evaluation will be increased. This new staging system is not intended to be a substitute for the INSS, and it is recommended that both systems be used in parallel. Stage L1 tumors are localized tumors that do not involve vital structures, as defi ned according to the list of IDRFs. The tumor must be confi ned within one body compartment: the neck, chest, abdomen, or pelvis. The isolated fi nding of intraspinal tumor extension that does not fulfi ll the criteria for an IDRF is consistent with stage L1 disease.
Stage L2 tumors are local-regional tumors with one or more IDRFs. The tumor may be ipsilaterally continuous groups. However, the INSS is not suitable for the pretreatment risk classification of patients with localized disease as this staging is based on the extent of tumor removal ( 8 ) . Actually, the same tumor can be classifi ed as INSS stage 1 or 3 disease depending on the extent of surgical excision ( 9 ) , making direct comparisons of clinical trials based on the INSS diffi cult. Furthermore, the localized disease of patients whose "treatment" is observation because spontaneous tumor regression is anticipated cannot be properly staged by using the INSS. Assessment of lymph node involvement is also diffi cult to apply uniformly ( 8 ) .
In 2004, investigators from the major cooperative groups-the Children's Oncology Group (COG) from North America and Australia-New Zealand, the German Pediatric Oncology and Hematology Group (GPOH), the Japanese Neuroblastoma Study Group (JNBSG), and the International Society of Pediatric Oncology Europe Neuroblastoma (SIOPEN) Group-and China formed the International Neuroblastoma Risk Group (INRG) Task Force, which developed the INRG Staging System (INRGSS) and the INRG Risk Classifi cation System for neuroblastoma ( 2, 8 ) . The INRGSS, published in 2009, is designed for tumor staging before surgery or any other treatment ( Table 2 ) ( 8 ) . Localized tumors are classifi ed as stage L1 or L2 disease on the basis of whether one or more of 20 IDRFs are present ( Table 3 ) ( 8 ) . IDRFs are surgical risk factors, detected on images, that make total tumor excision risky or diffi cult at the time of N euroblastic tumors (ie, neuroblastoma, ganglioneuroblastoma, ganglioneuroma) are the most common extracranial solid tumors occurring in children ( 1 ) . The median age at diagnosis is about 16 months, and 95% of cases are diagnosed by 7 years of age ( 2, 3 ) . The most common sites of origin of neuroblastic tumors are the adrenal region (48%), extraadrenal retroperitoneum (25%), and chest (16%). Less common sites are the neck (3%) and the pelvis (3%) ( 2 ) . Forty-eight percent of patients have metastatic disease at diagnosis ( 2 ) .
The enigmatic nature of this tumor group has long been recognized: Some tumors undergo spontaneous involution without any therapy, while others progress with a fatal outcome despite the implementation of maximal modern therapy ( 3 ). Fortunately, strong prognostic factors can be used to accurately predict whether children have "good" or "bad" disease at diagnosis ( 4 ) . Clinical stage is currently the most statistically significant and clinically relevant prognostic factor ( 2 ). Other factors include patient age, serum lactate dehydrogenase level, histologic category and grade of tumor differentiation ( 5 ), status of the MYCN oncogene, DNA ploidy, aberrations of chromosomes 1p and 11q, and genomic profi le ( 5 ) . Combinations of biologic factors with age and clinical stage have been used as stratifying criteria to defi ne risk groups ( 2 ) , and current treatment protocols are stratifi ed according to risk. Thus, accurate staging at the time of diagnosis is of paramount importance.
The International Neuroblastoma Staging System (INSS) ( Table 1 ) , developed in 1988 (7) and modifi ed in 1993 (6) , is still used by most cooperative
Implications for Patient Care
Use of a uniform imaging strategy n will facilitate the staging of neuroblastic tumors.
Consistent and uniform reporting n and staging will greatly facilitate comparisons of risk-based clinical trials conducted in different regions of the world.
Patients with neuroblastoma n worldwide will likely benefi t from the early recognition of effective treatment regimens with improved outcomes.
Advance in Knowledge
This consensus report, written by n experts representing the major international cooperative pediatric cancer study groups, will likely optimize imaging and uniform reporting for neuroblastoma staging according to the new International Neuroblastoma Risk Group Staging System.
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report. Although ganglioneuroma is a localized tumor and tends to be relatively homogeneous, the imaging characteristics of neuroblastoma, ganglioneuroblastoma, and ganglioneuroma are similar ( 13 ) . The histologic type cannot be discriminated with imaging and is based on pathologic analysis fi ndings only. The diagnosis of neuroblastic tumor is usually suspected with a high degree of confi dence on the basis of the patient's age and imaging pattern. Before obtaining pathologic specimens or specific markers (urinary catecholamines, MIBG uptake), the most usual challenge is the differential diagnosis of renal versus extrarenal retroperitoneal tumor-that is, neuroblastoma versus Wilms tumorsince both of these neoplasms occur during childhood ( 18 ) . Multiplanar imaging the chairs of their respective cooperative groups (INRG, SIOPEN, COG, JNBSG, GPOH). The present recommendations from this group were developed in consensus on the basis of professional experiences and review of the literature. This consensus report is provided to optimize imaging and uniform reporting for staging of neuroblastic tumors and to facilitate comparisons of risk-based clinical trials conducted in different regions of the world.
Imaging of Primary Tumors

Imaging of Neuroblastic Tumors
The imaging patterns of neuroblastic tumors have been thoroughly described (10) (11) (12) (13) (14) (15) (16) (17) and are beyond the scope of this within body compartments-for example, a left-sided abdominal tumor with left-sided chest involvement should be considered stage L2 disease. However, a clearly left-sided abdominal tumor with right-sided chest (or vice versa) involvement is defi ned as metastatic disease.
Stage M tumor refers to distant metastatic disease (ie, not contiguous with the primary tumor), except as defi ned for stage MS. Nonregional (distant) lymph node involvement is metastatic disease. However, an upper abdominal tumor with enlarged lower mediastinal nodes or a pelvic tumor with inguinal lymph node involvement is considered local-regional disease. Ascites and pleural effusion, even with malignant cells, do not constitute metastatic disease unless they are remote from the body compartment of the primary tumor.
Stage MS tumor refers to metastatic disease in patients younger than 18 months (547 days), with the metastasis confi ned to the skin, liver, and/or bone marrow. Bone marrow involvement should be limited to less than 10% of all nucleated cells in the culture smears or biopsy samples. Iobenguane I 123 (MIBG) scintigraphy fi ndings must be negative in bone and bone marrow. Provided there is MIBG uptake in the primary tumor, bone scans are not required. The primary tumor can be with or without IDRFs (stage L2 or L1), and there is no restriction regarding crossing or infi ltration of the midline.
The INRGSS has profound implications for imaging, and the radiologist's infl uence is clearly increased. Further discussion regarding the defi nitions and importance of the IDRFs was perceived to be necessary. Therefore, an international group of neuroblastoma experts was formed to prepare this special report to disseminate recommendations for imaging and staging. There currently is no consensus about the optimal imaging modality for assessing local disease. Both MR imaging and CT are routinely used, depending on local availability and the radiologist's preference. In one multiinstitutional study ( 20 ) , CT and MR imaging had statistically similar but relatively poor performance in assessing the features of local disease. However, the aim of that study was to assess the relevance of imaging for assessment of INSS stage but not IDRFs. In the absence of evidencebased criteria, we describe the advantages and limitations of both modalities in the following text.
CT is widely available in imaging departments, and current multidetector CT machines allow very fast acquisitions without motion artifacts, reducing the need for sedation. Intraspinal extension is also well depicted, and postprocessing software allows multiplanar reconstructions for accurate coronal and sagittal views. However, with CT, the use of intravenous iodine-based contrast material (with its potential risks) is required to increase the soft-tissue contrast and assess the relationships between the tumor and adjacent vessels. Moreover, CT is associated with substantial radiation exposure, and children are known to have a higher inherent sensitivity to the negative effects of ionizing radiation ( 21 ) . Nevertheless, for patients requiring radiation therapy, CT is still the reference-standard technique for defi ning the radiation fi elds and dose planning ( 22 ) . A preoperative CT study is therefore usually required in trials where the postoperative radiation fi eld is determined on the basis of the preoperative (postinduction) residual tumor extension. However, although MR imaging is not yet widely available or used for patients with neuroblastoma, there is currently increasing use of this examination as a treatment-planning method ( 23 ) .
MR imaging has long been recognized as an effective method for imaging neuroblastoma ( 10,14,16,17,20 ); however, to our knowledge, its superiority
Rationale for Use of Imaging Modalities
When an abdominal or pelvic tumor is suspected in a child, ultrasonography (US) is usually the fi rst imaging examination performed because of its wide availability and noninvasiveness. Gray-scale and duplex Doppler US allows accurate localization of neuroblastoma and can help defi ne the relationship of this tumor with adjacent organs and vessels. US is also quite effective for imaging the liver in children. In newborns, US may even depict intraspinal involvement. However, US is associated with important limitations: low interobserver reproducibility, limited assessment of highly calcifi ed tumors because of acoustic shadowing, and marked restrictions in the retrospective data review that is mandatory for clinical trials. Surgeons and radiation oncologists also require more extensive imaging for treatment planning. Therefore, analysis usually allows demonstration of the renal or extrarenal origin of the mass. However, a large neuroblastoma invading the kidney can be mistaken for an exophytic Wilms tumor, and vice versa.
Local extension of neuroblastoma mainly consists of perivascular involvement with arterial encasement, infi ltration of adjacent soft tissues and organs (mainly the kidneys and liver), and infi ltration of the foramina and epidural space of the spinal canal when the primary tumor arises from a paraspinal sympathetic chain. Lymph node involvement occurs in about 30% of cases. Lymph nodes are usually located close to the primary tumor, although distant lymph nodes (previously classifi ed as stage 4N tumors if there were no other metastatic sites) may be observed occasionally ( 19 ) . 
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tumor and the neighboring structure ( Fig E3 [online] ). When a tumor is separated from a vital structure, an IDRF is not present. 2. Contact means that no visible layer is present between the tumor and the neighboring structure. For an artery, contact means that less than 50% of the vessel's circumference is in contact with the tumor ( Fig 3 , Fig E4  [online] ). In addition, the term f lattened is used to describe veins with a reduced diameter that still have a partially visible lumen ( Figs 2, 3 , Fig E5 [online]). When a tumor is in contact with a vital structure or is fl attening a vein without encasement, an IDRF is not present, except in the case of renal vessels (see following text).
3. Encasement means that the neighboring structure is surrounded by the tumor. When a tumor is encasing a vital structure, according to previous defi nitions, an IDRF is present. Encasement of a vessel means that more than 50% of the circumference is in contact with the tumor ( Figs 2-5 , Fig E6 [online] ). Total encasement means that a vital structure (organ or vessel) is completely surrounded by the tumor. A fl attened vein with no visible lumen is also considered to be encased.
4. Compression is used only when referring to the airways. When a tumor is in contact with the airways and causes the short axis of the airways to be reduced ( Figs 5, 6 , Fig E5 [online]), this pattern is considered an IDRF. For other vital structures (ie, neighboring organs), a contact may be associated with displacementthat is, an abnormal anatomic location-or distortion-that is, an abnormal anatomic shape-of the structure (Figs E7, E8 [online]). However, these situations are not considered IDRFs unless there is infi ltration or total encasement.
5. Infi ltration refers to involvement of vital structures other than vessels. Infi ltration of the vessel wall cannot be demonstrated at imaging. An infi ltrating tumor has extension into a neighboring organ, causing the margins between the tumor and the infi ltrated structure to be lacking or ill defi ned (Fig E8 tumor should always be assessed to aid surgical decisions.
For patients who are either observed only or treated with primary chemotherapy, imaging has to be repeated, either to document tumor regression or as a preoperative assessment. Since an IDRF may disappear with tumor regression ( 26 ) , reporting should include reassessment of the patient's IDRF status. A checklist of IDRFs is provided as supplemental material (Fig E13 [online] ) to facilitate and ensure uniform and correct staging at diagnosis; however, this checklist is not intended to be a substitute for the local radiologist's report.
Anatomic Compartments and Multifocality
Most tumors occur in a single anatomic compartment (ie, neck, chest, abdomen, pelvic cavity). However, some tumors may extend into an adjacent compartment. This extension often increases the risk of injury to vital structures during surgery, and such lesions should be classifi ed as stage L2 tumors, even if no other IDRF is present in each compartment. This usually occurs with cervicothoracic lesions arising from the sympathetic chain ( 25 ) , lower mediastinal tumors extending into the retroperitoneum along the aorta ( Fig 1 ) , upper retroperitoneal tumors extending into the inferior mediastinum ( Fig 2 ) or pelvis, or pelvic presacral tumors extending either upward in the abdomen around the aorta or inferior vena cava or laterally through the greater sciatic foramen.
Multifocal primary neuroblastomas are rare and may be familial ( 27, 28 ) . They can manifest as synchronous or metachronous noncontiguous tumors. When multifocal tumors occur, each neoplasm should be staged according to the greatest extent of disease. This special feature should be recorded but by itself is not considered an IDRF.
Defi nitions of Terms to Describe Relationships between Primary Tumor and Vital Structures
We recommend that the following terms be used to describe the primary tumor:
1. Separation means that a visible layer, usually fat, is present between the over CT for local-regional staging has not been demonstrated. Compared with CT, MR imaging offers the advantages of higher contrast resolution and the lack of ionizing radiation. There is an ongoing unresolved discussion regarding the need for gadolinium-based contrast material injection to assess neuroblastoma extension. Gadolinium-based contrast material may improve the assessment of infi ltration into adjacent tissues and tumor vascularity. However, T1-and T2-weighted sequences provide excellent contrast resolution, and vessels can be displayed suffi ciently without the use of contrast material ( 16 ) . In one study, the accuracy of T2-weighted and gadolinium-enhanced T1-weighted sequences in defi ning the local-regional tumor extent were compared, and no difference was found ( 24 ) .
The main limitations of MR imaging are the local availability in some countries and, as compared with CT, the need for sedation in young children because of the longer acquisition time. In patients with intraspinal extension of primary paraspinal tumors, MR imaging is the recommended imaging modality ( 14, 25 ) because of the excellent visualization of the spinal cord, nerve roots, and subarachnoid spaces. Specifi c technical recommendations for imaging neuroblastic tumors in children, including CT scanning settings, MR sequences, three-dimensional measurement methods, and data storage, are provided in the Appendix (online).
Recommended Terms to Describe IDRFs
To ensure uniform tumor staging, it is recommended that radiologists use specifi c terms to describe the relationships between tumors and the neighboring vital structures-those entities that cannot be sacrifi ced without impairing function. As a part of treatment planning, these relationships should be systematically discussed by a multidisciplinary team that includes ideally radiologists, nuclear medicine physicians, surgeons, and pediatric oncologists.
Although metastatic disease (stage M or MS) is staged regardless of the local-regional tumor extent, the absence or presence of an IDRF for the primary
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[online]). When a tumor infi ltrates a vital structure, an IDRF is present. 6. The term invasion was also originally included in the IDRF list to describe relationships with the renal pedicle ( 8 ); however, this is a less welldefi ned term. Because surgical dissection of the renal pedicle is particularly risky in patients with neuroblastoma, it was decided that an IDRF is present even if the strict criteria for encasement are not fulfi lled-that is, even if the tumor is in contact with the renal vessels only. (This specifi c location is addressed in the following section.) The term invasion was also used to describe spinal canal involvement and is equivalent to the term infi ltration for this specifi c location. (This specifi c location is addressed in the following section.)
IDRF Assessment Based on Anatomic Location
Cervical neuroblastomas arise mainly from the superior cervical sympathetic chain behind the internal carotid artery. These tumors usually extend anteriorly and laterally, displacing the carotid artery and internal jugular vein. They may also extend medially, compressing the airway (Fig E5 [online] ), and upward to the skull base along the carotid artery. Intraspinal extension is usually not observed at this anatomic level. IDRFs are present when the tumor encases the carotid artery ( Fig 4 ) , vertebral artery, or internal jugular vein; extends to the 
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Brisse et al complications is considerably increased. Associated foraminal and intraspinal extensions are also possible. IDRFs are present when the tumor encases the brachial plexus roots, subclavian vessels, or vertebral or carotid artery or when it compresses the trachea ( Fig 5 ) . Most thoracic neuroblastomas arise from the paraspinal sympathetic chains in the posterior mediastinum. Foraminal and intraspinal extensions (ie, dumbbell tumors) are often present at this anatomic level. Surgical removal of the intraspinal component is usually not recommended at diagnosis, but it may be necessary as an emergency procedure in the presence of acute neurologic symptoms caused by spinal cord compression or ischemia. Cord compression may be diagnosed because of neurologic signs or on the basis of imaging fi ndings. An IDRF is present when more than one-third of the spinal canal in the axial plane is invaded (ie, infi ltrated) ( Figs 1, 6, Fig E9 [online] ), the leptomeningeal fl uid spaces are no longer visible, or the spinal cord MR signal intensity is abnormal (ie, imaging features that are usually observed in patients with neurologic symptoms).
A lower mediastinal tumor, infi ltrating the costovertebral junction between the T9 through T12 vertebral levels, is associated with a theoretical risk of spinal cord ischemia caused by surgical injury of the anterior spinal (Adamkiewicz) artery ( 29 ) and by itself is considered an IDRF (Fig E4 [online] ). However, the risk of injury to the spinal cord is very low in children, probably because of the abundant collateral blood fl ow that develops in response to the rather slow growth of most tumors in this location. Thus, angiography is not mandatory, even if it is performed with noninvasive methods such as CT or MR imaging.
The other major surgical diffi culties are related to relationships with the descending aorta and the pulmonary pedicles. Encasement of the aorta ( Fig 1 , Fig E9 [online] ) or major branches, compression of the trachea or principal bronchi ( Fig 1 ) , and infi ltration of adjacent structures such as the pericardium, pleura ( Fig 1 ) , and diffi culties ( 26 ) . The stellate ganglion is located above the subclavian artery at the level of the origin of the vertebral artery. When dissection of neurovascular elements in this region is needed for tumor excision, the risk of surgical skull base ( Fig 4 ) ; or compresses the trachea.
Cervicothoracic neuroblastomas arising from the region of the stellate ganglion are rare but associated with particular imaging patterns and surgical 
Brisse et al diaphragm are considered IDRFs. In our experience, the diffi culties in surgically dissecting infi ltrating mediastinal tumors obviously arising from the periaortic sympathetic plexuses are usually the same as those encountered with infi ltrating periaortic abdominal tumors. At imaging, these tumors are ill-defi ned masses infi ltrating adjacent structures, and they differ from wellcircumscribed tumors (Fig E4 [online] ) arising from paravertebral sympathetic chains.
Abdominal neuroblastomas arise from the adrenal gland, sympathetic ganglia (celiac, superior, and inferior mesenteric ganglia), or sympathetic fi bers and plexuses along the aorta and its main branches. The intimate relationships between the primary tumor and abdominal vessels usually represent the main challenge for the surgeon. Therefore, accurate analyses and descriptions of all arteries and veins are critical parts of the imaging reports. The main abdominal vessels (aorta, celiac axis, superior and inferior mesenteric arteries, renal arteries and veins, inferior vena cava, iliac arteries and veins, portal vein) should be separately assessed and classifi ed according to the terms just defi ned. Tumors partially or totally encasing the origin of the celiac axis ( Figs 2, 7 ) , the superior mesenteric artery, the aorta ( Fig 1, Fig  E6 [online] ), one or both renal pedicles ( Figs 2, 7, Fig E6 [online] ), the inferior vena cava, or the iliac vessels (Fig E10  [online] ) are IDRF positive. Since injury to the inferior mesenteric artery almost never causes complications, encasement of this vessel is not by itself an IDRF.
Renal pedicles are frequently involved in retroperitoneal neuroblastomas. In the fi rst study of the Localized Neuroblastoma European Study Group ( 30 ) of the International Society of Pediatric Oncology, 51% of patients with localized abdominal neuroblastoma had IDRFs, and 45% of these had involvement of the renal pedicles. In the Shamberger et al series ( 31 ) , 15% of children treated for abdominal neuroblastoma required nephrectomies or had a renal infarction during surgery. Furthermore, the risk for nephrectomy in children who underwent tumor excision up front 
Brisse et al was twice that of those who underwent resection after chemotherapy. Therefore, even isolated contact with renal vessels is considered an IDRF-positive condition ( Fig 8 ) .
The adjacent organs and structures should also be precisely assessed and classifi ed according to the earlier defi ned terms. Tumors infi ltrating the porta hepatis (liver hilum) ( Fig 7 ) , diaphragm ( Fig 2, Fig E11 [online] ), kidneys ( Figs  E6, E8 [online] ), liver, duodenopancreatic block ( Fig 7, Fig E6 [online] ), or mesentery ( Fig E12 [online] ) are IDRF positive. Neuroblastomas arising from the inferior mesenteric region (organ of Zuckerkandl) more frequently infi ltrate the mesentery ( 32 ) than do neuroblastomas in other locations. Regarding the kidneys, infi ltration may occur directly through the cortex (usually from adrenal neuroblastomas) (Fig E8 [online] ) or through the hilum along renal vessels (Fig E6 [online] ) (usually from retroperitoneal neuroblastomas).
Lumbar paraspinal neuroblastomas are much less common. Frequently classifi ed as having abdominal locations because of their anterior extension, these tumors are different from the above described retroperitoneal ones. They may be associated with foraminal and intraspinal extension (dumbbell tumors) (Fig E11 [online] ), sharing the same pattern and neurologic issues as mediastinal primary tumors. As in the mediastinum, an IDRF is present when more than one-third of the spinal canal in the axial plane is invaded (Fig E11 [online] ), when the leptomeningeal spaces are not visible, or when the spinal cord MR signal intensity is abnormal. Tumors involving the lumbar plexus (Fig E10 [online] ) are associated with the inherent risk of surgical injury and should be classifi ed as IDRF positive.
Pelvic neuroblastomas arise mainly from the upper hypogastric sympathetic plexus or presacral sympathetic ganglia. Pelvic organs are usually anteriorly displaced but not infi ltrated. Major extension occurs along the iliac vessels and into the lumbosacral foramina. Tumors encasing the aorta, inferior vena cava, or iliac vessels (Fig E10 [online] ) are considered IDRF positive. Posterior lumbar 
Brisse et al using both imaging and bilateral bone marrow aspirate and biopsy. Distant metastases must be assessed by using MIBG scintigraphy, and the study must be performed before tumor excision ( Fig 10 ) ( 8,34 ) . Guidelines have been published for MIBG scanning in children (34) (35) (36) .
Since there is no physiologic uptake of MIBG in bone or bone marrow, MIBG scanning is an accurate method for detecting osteomedullary metastases ( Fig 10 ) , with sensitivity and specifi city estimated at 90% and 100%, respectively ( 37, 38 ) . MIBG single photon emission computed tomography (SPECT) enables better depiction of the small focal uptake that is diffi cult to visualize on planar MIBG scans, especially in areas close to intense physiologic uptake such as the traindication to primary excision of the extraspinal tumor component. More rarely, tumors extend laterally into the gluteal region through the greater sciatic foramen; this condition is also considered to be IDRF positive. On axial CT and MR images, the anatomic level of the greater sciatic foramen is defi ned by a sagittal-oblique line between the spine of the ischium and the lateral margin of the sacrum ( Fig 9 ) .
Imaging of Metastatic Disease
Bone Marrow and Bone Metastases Distant metastases of neuroblastomas are located primarily in bone marrow (70%) or bone (55%) ( 33 ) . Bone marrow involvement must be assessed by or sacral foraminal extensions are IDRF negative, but intraspinal extension is IDRF positive when more than one-third of the spinal canal in the axial plane is invaded.
Intraspinal tumor extension below the level of the L2 vertebra leads to radicular involvement ( Fig 9 ) rather than spinal cord compression. This condition sel dom leads to emergency neurosurgery and is usually not a con- 
SPECIAL REPORT: Guidelines for Imaging and Staging Neuroblastic Tumors Brisse et al
If required in a specifi c study, dedicated conventional radiography or CT may be helpful in patients with MIBG-positive osteomedullary metastases for distinguishing bone marrow from cortical bone involvement. The role of fl uorine 18 fl uorodeoxyglucose (FDG) positron emission tomography (PET) in the setting of neuroblastoma is still under investigation. The feasibility of PET in young children, the associated radiation exposure, and the higher cost, as compared with those associated with MIBG scanning, may explain the hitherto limited use of this technique. Another limitation is the high physiologic uptake of FDG in the brain, which may hide skull locations. However, FDG PET may help defi ne the distribution of neuroblastomas that fail to take up MIBG ( 42,45 ) ( Fig 12 ) . FDG PET is superior for before examination) ( 8 ) . Bone scan has a reported sensitivity of 70%-78% and a specifi city of 51% for the detection of bone metastases ( 38, 42 ) . The high physiologic uptake of the growing metaphyses in children, especially infants, may be misinterpreted as metastases or hide small metastases ( 43 ) .
Skeletal surveys have previously been recommended for infants with negative bone scan fi ndings ( 7, 43 ) . However, in our experience, these rarely add important information and accordingly are not considered helpful. CT examinations performed to assess local disease also commonly depict bone metastases. Although CT was used in some previous protocols as a prognostic part of the staging ( 44 ) , it is known to be inaccurate for detecting bone metastases because of its low sensitivity compared with that of MIBG or bone scan ( 20 ) . liver and the bladder. Postprocessing tools also enable fusion of SPECT and CT images ( Fig 11 ) , improving anatomic localization (39) (40) (41) .
One unequivocal MIBG-positive lesion at a distant site is suffi cient to defi ne metastatic disease. However, a single equivocal lesion on MIBG scans requires confirmation with another imaging modality-namely, conventional radiography, and MR imaging or CT if the radiographic fi ndings are negative-or with biopsy. To better assess the extent of disease and the response to therapy, the use of a semiquantitative scoring system is strongly recommended ( 34 ) .
Technetium Tc 99m medronate bone scintigraphy is usually not required, except in cases in which the primary tumor is not MIBG avid or MIBG positivity cannot be confi rmed (ie, if the primary tumor has been removed 
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Brisse et al diffusion restriction because of high cellular density ( 55 ) . Therefore, MR imaging could become a major imaging tool in children, allowing staging of both localregional and distant disease. However, further studies are needed to assess the accuracy of this imaging strategy.
Other Metastatic Sites
The anatomic location of involved lymph nodes should be precisely assessed. An upper abdominal tumor with contiguous or noncontiguous enlarged lower mediastinal nodes or a pelvic tumor with contiguous or noncontiguous inguinal lymph nodes is considered local-regional disease. However, distant (nonregional) lymph nodes depicted by CT, MR imaging, or MIBG scanning (eg, supraclavicular lymph nodes associated with retroperitoneal primary tumor) are considered metastatic (stage M) disease. Liver and subcutaneous metastases are mainly observed in infants (Pepper syndrome, stage 4S or MS) ( 33 ) . Liver metastases can be assessed with US, CT, or MR imaging. Liver metastases may manifest in one of two forms: focal masses or diffuse infi ltration. The latter results in children showed whole-body MR imaging to have higher sensitivity than bone scan for the detection of bone marrow metastases (50 ,51 ) , and the short-tau inversion-recovery sequence was described as an effi cient sequence in children with small cell tumors (47 ,48 ) . One small series (51) involving patients with neuroblastoma provided encouraging results: Whole-body MR imaging had higher sensitivity than MIBG scintigraphy. However, compared with MIBG scintigraphy, whole-body MR imaging has several limitations. The fi rst limitation is the low specifi city of MR signal intensity abnormalities. Wholebody MR imaging also has low predictive value in the detection of extraskeletal metastases (51) . Finally, the capability of MR imaging for assessing tumor response has not been reported in patients with neuroblastoma, whereas MIBG scoring is possible and aids in assessing therapeutic response.
Diffusion-weighted MR imaging has been described as a promising tool for assessing metastatic response to therapy for various neoplasms ( 52-54 ), and neuroblastoma is known to demonstrate demonstrating soft-tissue lesions and INSS stage 1 and 2 tumors, but MIBG scanning is more sensitive for the detection of bone metastases ( 45, 46 ) .
The role of whole-body MR imaging in bone marrow assessment is still not defi ned in patients with neuroblastoma. In the fi rst publications related to the MR assessment of bone and bone marrow metastases from neuroblastoma, this method demonstrated high sensitivity (47 ,48 ) . The combination of nonenhanced and gadolinium-enhanced T1-weighted MR sequences has been considered the optimal method ( 49 ). In one large study ( 20 ) comparing the accuracies of CT, MR imaging, and bone scan in staging neuroblastoma, MR imaging alone and bone scan alone yielded similar results for the depiction of skeletal metastases. However, in that study, the whole skeleton was not assessed with MR imaging, and MIBG scintigraphy was not included for comparison.
During the late 1990s, whole-body MR imaging was reported as an effective method for the depiction of bone and bone marrow metastases. Early 
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Although not a staging issue, when skull base involvement is clinically suspected or depicted on MIBG or bone scans, brain MR imaging or CT should be performed to detect optic nerve compression ( 63 ) , which may require emergency treatment. Figure 13 is a fl owchart of the imaging strategy at diagnosis for patients with neuroblastomaboth local-regional disease and distant metastases-including mandatory and optional examinations.
Conclusion
Patients with neuroblastoma should be stratifi ed at the time of diagnosis on the basis of reproducible imaging criteria. Increased focus on imaging enhances the role of radiologists in diagnosis and treatment planning.
Treatment strategies must be decided by the individual cooperative groups. Nevertheless, an international group has for many years used the absence of IDRFs to select patients for primary surgical treatment ( 30 ) . It is therefore anticipated that the knowledge accumulated on the basis of the concept of IDRFs will become an increasingly larger integrated part of therapy planning, both for treatment protocols and for individual patients.
These guidelines can be considered a platform for further studies. As with all projects involving international collaboration, compromises had to be made to reach consensus guidelines and recommendations. However, with continuous efforts, these can be improved and updated as needed. To do so, new and accurate information has to be acquired. If incorporated into protocols and used systematically, the guidelines will facilitate the collection of consistent and standardized data that will be useful for evaluating the effect of IDRFs on patient outcomes. pattern is primarily observed in infants and is sometimes missed at CT because it may uniformly increase the parenchymal attenuation ( 13 ) , although the liver is usually enlarged.
Lung and pleural metastases are more common among patients with MYCN -amplifi ed tumors, but they are rarely observed (3.6% of patients with INSS stage 4 disease) ( 56 ) and therefore are not routinely screened for with CT. The CT pattern of lung metastases is nonspecifi c ( 57 ) . CT is the best method for assessing these metastases since both MIBG scintigraphy and FDG PET have low sensitivity in depicting small lung nodules. However, hybrid MIBG SPECT and combination PET/CT machines will benefi t from the high sensitivity of CT for better lesion depiction.
Although pleural disease is associated with reduced survival rates in patients with metastatic disease ( 57 ), isolated pleural effusion (or ascites) is rare in patients with local-regional disease, and its effect on outcome is still unclear. Therefore, effusions and ascites should be recorded, but these fi ndings alone are not considered IDRFs, and neither condition is considered metastatic disease.
Central nervous system parenchymal or meningeal metastatic spread is also very rare and is usually observed during recurrences ( 58, 59 ) . Therefore, it is usually not systematically screened for at diagnosis unless specifi c symptoms (other than those related to spinal cord compression) are present. The radiologic features of central nervous system metastases vary from single large parenchymal lesions with possible cystic or hemorrhagic features or calcifi cations to diffuse meningeal involvement ( 58,60-62 ).
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